Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Sandoz’ Generic Drug Push in Japan: Good Timing; Interesting Challenges

October 7, 2009

Analysis of:Sandoz Plans to Sell More Drugs in Japan, May Acquire Companies | www.bloomberg.com

Novartis AG's generic pharmaceutical unit, Sandoz AG's timing for entry into the Japanese pharmaceutical market is excellent as seismic forces in the market make generic drugs more attractive than ever. Sandoz CEO Jeff George's challenges include a prestige-driven hospital system and a private practice/physician medical practice that rewards branded pharmaceuticals. But Sandoz and Novartis could capitalize on some crucial allies in their fight.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS